Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Teladoc Health Q3 2026 Results: Net Loss of $26.9M, Loss Narrows

Teladoc Health reported a revenue decrease to $605.1 million for the third quarter of 2026 compared to $626.4 million in the prior year period. The company's net loss narrowed to $26.9 million, or $0.15 per share, while cash and cash equivalents increased to $849.9 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue605.1626.4
Profit before tax-26.3-50.2
Net income-26.9-49.5
EPS (diluted, $ a share)$-0.15$-0.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-3.4%
Operating margin-4.6%
Source

10-Q filed with the SEC, NYSE: TDOC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Teladoc Health, Inc.: key numbers

Share price
$8.70Close, Nov 16
Market cap
$1.59B
Shares outstanding
182.29MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Offices & Clinics of Doctors of MedicineSIC 8011

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Teladoc Health, Inc.

All →
4:33 PM ET Form 4
Insider Selling

Teladoc Health President, International Carlos Nueno Sells $271K of Stock

Carlos Nueno, President, International, sold 29,432 shares of Teladoc Health, Inc. at $9.20 a share, worth $271K in total on Nov 6, 2026. Shares held after the trade: 35,312 (-45.5%).

Value
$271K
Shares
29,432
Price
$9.20
Role
President, International
Holding change
-45.5%
Trade date
Nov 6, 2026
4:05 PM ET 8-K
Financial Results

Teladoc Health Financial Results

Teladoc Health reported third quarter 2026 revenue of $605.1 million, a 3% decrease year-over-year, driven by a 13% decline in its BetterHelp segment. The company narrowed its net loss to $26.9 million ($0.15 per share) compared to $49.5 million in the prior year, while adjusted EBITDA grew 14% to $79.4 million.

Term
Q3 2026

“We delivered third quarter results near the upper end of our guidance range for consolidated revenue and above our range for consolidated adjusted EBITDA, reflecting solid execution across our two segments.”

Chuck Divita, Chief Executive Officer of Teladoc Health

“Within the Integrated Care segment, we continue to advance our innovation agenda, including the implementation of Teladoc One with our early launch partners, while also expanding our capabilities through initiatives such as hybrid care and AI-enabled solutions.”

Chuck Divita, Chief Executive Officer of Teladoc Health
8:30 AM ET 8-K
Leadership Change

Teladoc Health Leadership Change

Adam C. Vandervoort, Chief Legal Officer and Secretary, has resigned effective November 1, 2026, citing 'good reason' under his severance agreement. He will be succeeded by Jonathan Dorfman, the current SVP of Securities & Corporate Law, while Vandervoort provides unpaid advisory services through November 2027 to assist with the transition.

4:06 PM ET Form 4
Insider Selling

Teladoc Health CEO Charles Divita III Sells $109K of Stock

Charles Divita III, CEO, sold 17,805 shares of Teladoc Health, Inc. at $6.10 a share, worth $109K in total on Sep 11, 2026. Shares held after the trade: 465,535 (-3.7%).

Value
$109K
Shares
17,805
Price
$6.10
Role
CEO
Holding change
-3.7%
Trade date
Sep 11, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.